A Study of JNJ-80202135 in Healthy Chinese Adult Participants

计划入组 30 人 · 首次发布于 2021 年 12 月 9 日

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

计划入组 115 人 · 首次发布于 2025 年 10 月 16 日

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

计划入组 48 人 · 首次发布于 2021 年 7 月 22 日

Nipocalimab(Imaavy)

Rx

AAHI-SC3

AAHI-SC2

ASIAN AMERICAN HEALTH COALITION (AAHC) OF THE GREATER HOUSTON AREA

United States

FDA Approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) as First Therapy for Warm Autoimmune Hemolytic Anemia

Nipocalimab Demonstrates Significant Efficacy in Phase 2 Sjögren's Disease Trial Published in The Lancet

Johnson & Johnson Seeks FDA Approval for First-Ever Treatment of Rare Blood Disorder wAIHA